Literature DB >> 9620903

Circulating immunoreactive interleukin-6 in cystic fibrosis.

L S Nixon1, B Yung, S C Bell, J S Elborn, D J Shale.   

Abstract

We measured circulating and sputum-sol concentrations of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), neutrophil elastase-alpha1-antiproteinase complex (NEAPC), and C-reactive protein (CRP) in an exacerbation, after antibiotic treatment, and in clinically stable patients with cystic fibrosis and chronic pulmonary infection with Pseudomonas aeruginosa. The aim was to determine the compartmental patterns of a proinflammatory and anti-inflammatory cytokine compared with other markers of inflammatory activity in cystic fibrosis. IL-6, NEAPC, CRP, and absolute neutrophil count were reduced after antibiotic treatment, p < 0.01. IL-6 and CRP concentrations were greater, p = 0.007, and p = 0.01, respectively, in a stable group of patients compared with those at the end of an exacerbation. IL-6 and CRP concentrations were related (r = 0.836, p < 0.0001), and both were greater than in matched control subjects (p < 0.001) at all times studied. Sputum-sol concentrations of IL-6 after treatment were positively related to FEV1 and FVC and inversely related to concentrations of neutrophil elastase. The separation between patients and healthy subjects, and the reduction of IL-6 after antibiotic treatment indicates it could be used as a marker of inflammation, but its relationship to other markers depends on the compartment in which it is measured.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620903     DOI: 10.1164/ajrccm.157.6.9704086

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  36 in total

Review 1.  Growth and growth charts in cystic fibrosis.

Authors:  Leena Patel; Moira Dixon; T J David
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

Review 2.  Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers.

Authors:  Olivia Giddings; Charles R Esther
Journal:  Pediatr Pulmonol       Date:  2017-07-17

3.  Inflammatory markers of lung disease in adult patients with cystic fibrosis.

Authors:  Hara Levy; Leslie A Kalish; Ian Huntington; Nathaniel Weller; Craig Gerard; Edwin K Silverman; Juan C Celedón; Gerald B Pier; Scott T Weiss
Journal:  Pediatr Pulmonol       Date:  2007-03

Review 4.  Pyocyanin effects on respiratory epithelium: relevance in Pseudomonas aeruginosa airway infections.

Authors:  Balázs Rada; Thomas L Leto
Journal:  Trends Microbiol       Date:  2012-11-07       Impact factor: 17.079

Review 5.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

6.  Expression of S100A12 (EN-RAGE) in cystic fibrosis.

Authors:  D Foell; S Seeliger; T Vogl; H-G Koch; H Maschek; E Harms; C Sorg; J Roth
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

7.  Interleukin-6 blood levels in sensitive and multiresistant tuberculosis.

Authors:  J W Correia; M V Freitas; J A Queiroz; M PereiraPerrin; B Cavadas
Journal:  Infection       Date:  2008-11-08       Impact factor: 3.553

8.  Iron homeostasis during cystic fibrosis pulmonary exacerbation.

Authors:  Alex H Gifford; Lisa A Moulton; Dana B Dorman; Gordana Olbina; Mark Westerman; H Worth Parker; Bruce A Stanton; George A O'Toole
Journal:  Clin Transl Sci       Date:  2012-06-01       Impact factor: 4.689

9.  Serum insulin-like growth factor-1 (IGF-1) during CF pulmonary exacerbation: trends and biomarker correlations.

Authors:  A H Gifford; A B Nymon; A Ashare
Journal:  Pediatr Pulmonol       Date:  2013-06-18

10.  Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic fibrosis.

Authors:  C M Gordon; E Binello; M S LeBoff; M E Wohl; C J Rosen; A A Colin
Journal:  Osteoporos Int       Date:  2006-03-16       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.